F. Bagnato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
F. Bagnato has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
C. Gasperini
3 shared publicationsC. Pozzilli
3 shared publications- Enrico Millefiorini
La Sapienza University of Rome
2 shared publications O. Ciccarelli
2 shared publicationsS. Bastianello
2 shared publicationsS. Galgani
2 shared publications
Latest Publications
- 1 July 2004
- Published by Wiley in European Journal of Neurology
- Vol. 11 (7) , 455-460
beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis
- 1 July 2004
- Published by Wiley in European Journal of Neurology
- Vol. 11 (7) , 455-460
beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis
- 14 May 2002
- Published by Wolters Kluwer Health in Neurology
- Vol. 58 (9) , 1409-1411
A one-year study on the pharmacodynamic profile of interferon-β1a in MS
Interferon (IFN)-β1a induction of neopterin and β2-microglobulin (β2-MG) were evaluated over 1 year in patients with MS. Neopterin and β2-MG levels peaked 24 to 48 hours after weekly injections of IFNβ1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNγ expression and macrophage activation during IFNβ-1a treatment. Predose levels of β2-MG increased, the significance of which is as yet unclear.
- 14 May 2002
- Published by Wolters Kluwer Health in Neurology
- Vol. 58 (9) , 1409-1411
A one-year study on the pharmacodynamic profile of interferon-β1a in MS
Interferon (IFN)-β1a induction of neopterin and β2-microglobulin (β2-MG) were evaluated over 1 year in patients with MS. Neopterin and β2-MG levels peaked 24 to 48 hours after weekly injections of IFNβ1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNγ expression and macrophage activation during IFNβ-1a treatment. Predose levels of β2-MG increased, the significance of which is as yet unclear.
- 1 March 2000
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 6 (3) , 137-139
Antinuclear antibodies and response to IFNβ-1a therapy in relapsing-remitting multiple sclerosis
- 1 March 2000
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 6 (3) , 137-139
Antinuclear antibodies and response to IFNβ-1a therapy in relapsing-remitting multiple sclerosis
- 1 May 1998
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 4 (5) , 403-407
Determinants of Gd-enhanced MRI response to IFN-β-1a treatment in relapsing-remitting multiple sclerosis
- 1 May 1998
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 4 (5) , 403-407
Determinants of Gd-enhanced MRI response to IFN-β-1a treatment in relapsing-remitting multiple sclerosis